Brainstorm Cell Therapeutics Inc (BCLI)

Currency in USD
0.610
+0.030(+5.17%)
Closed·
BCLI Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
BCLI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5500.640
52 wk Range
0.5216.000
Key Statistics
Prev. Close
0.58
Open
0.55
Day's Range
0.55-0.64
52 wk Range
0.521-6
Volume
71.69K
Average Volume (3m)
1.36M
1-Year Change
-85.84%
Book Value / Share
-1.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCLI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.675
Upside
+3,289.34%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Brainstorm Cell Therapeutics Inc Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics Inc Earnings Call Summary for Q1/2025

  • BrainStorm Cell Therapeutics' stock surged 13.79% after ALS trial updates, with further 29.55% rise in premarket trading
  • Company initiating 200-patient Phase 3b trial for NurOwn ALS therapy, aiming to complete enrollment within 2-3 years
  • Actively pursuing $15 million non-dilutive grant and strategic partnerships to address financial constraints
  • CEO emphasized progress despite limited resources; company focused on NurOwn advancement and exosome program development
  • Analyst price targets range from $6.00 to $24.35, suggesting potential upside if clinical trials succeed
Last Updated: 19/05/2025, 14:18
Read Full Transcript

Compare BCLI to Peers and Sector

Metrics to compare
BCLI
Peers
Sector
Relationship
P/E Ratio
−0.6x−4.1x−0.5x
PEG Ratio
−0.010.010.00
Price/Book
−0.9x2.8x2.6x
Price / LTM Sales
-153.9x3.3x
Upside (Analyst Target)
-172.0%43.5%
Fair Value Upside
Unlock−0.7%6.9%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 20.675
(+3,289.34% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.45 / -0.97
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BCLI Income Statement

People Also Watch

1.1400
GNS
+34.12%
0.1082
OP
-7.60%
0.413
ADIL
-4.84%
0.656
MBRX
-4.24%

FAQ

What Stock Exchange Does Brainstorm Cell Therapeutics Trade On?

Brainstorm Cell Therapeutics is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Brainstorm Cell Therapeutics?

The stock symbol for Brainstorm Cell Therapeutics is "BCLI."

What Is the Brainstorm Cell Therapeutics Market Cap?

As of today, Brainstorm Cell Therapeutics market cap is 6.73M.

What Is Brainstorm Cell Therapeutics's Earnings Per Share (TTM)?

The Brainstorm Cell Therapeutics EPS (TTM) is -2.01.

From a Technical Analysis Perspective, Is BCLI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Brainstorm Cell Therapeutics Stock Split?

Brainstorm Cell Therapeutics has split 3 times.

How Many Employees Does Brainstorm Cell Therapeutics Have?

Brainstorm Cell Therapeutics has 29 employees.

What is the current trading status of Brainstorm Cell Therapeutics (BCLI)?

As of 07 Aug 2025, Brainstorm Cell Therapeutics (BCLI) is trading at a price of 0.61, with a previous close of 0.58. The stock has fluctuated within a day range of 0.55 to 0.64, while its 52-week range spans from 0.52 to 6.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.